Skip to main content
. 2012 Jan 10;20(4):759–768. doi: 10.1038/mt.2011.293

Figure 3.

Figure 3

Effects of gemcitabine on MYXV replication and oncolysis. (a) Hs766T cells were treated with the indicated concentrations of gemcitabine for 24 hours or left untreated and then infected with vMyx-GFP at MOI 10 in the presence of drug for 24 hours. Infected GFP-expressing cells were detected by direct fluorescence 24 hours p.i. Bar = 250 µm. (b) Gemcitabine sensitivity of pancreatic cancer cells. Hs766T cells and Pan02 cells treated with gemcitabine were analyzed for cell viability by MTT assays. MTT assays were performed in triplicate. (c) MYXV in combination with gemcitabine treatment enhances oncolysis. Hs766T cells or Pan02 cells were treated as indicated: Gemcitabine treatment followed by virus infection (G+V); virus infection followed by gemcitabine treatment (V+G); gemcitabine only (G). MTT assays were performed in duplicate or triplicate. Error bars for all MTT assays represent the mean plus/minus one standard deviation (mean ± SD). MOI, multiplicity of infection; MYXV, Myxoma virus; p.i., post infection.